AKR1B1 and diabetes mellitus: Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers were given alone or in combination in the Aldose Reductase Inhibitor-–Diabetes Complications Trial (medication rate, 25–50%), but there was no significant difference in medication rate between the control and epalrestat groups.